Skip to main content

Semaglutide is effective in type 2 diabetes and obesity with schizophrenia

Abstract

Background

Prevention and treatment of type 2 diabetes and obesity are problematic for individuals with schizophrenia partly because atypical antipsychotics and mental distress themselves increase appetite, thus promoting subsequent body weight gain and deterioration of glycemic control. Glucagon-like peptide-1 (GLP-1) receptor agonists have been gaining attention for their glucose-lowering and body weight-reducing effects in obese individuals with type 2 diabetes generally, but their effects in those also having schizophrenia have not been adequately addressed.

Case presentation

This case was a 50-year-old obese woman having type 2 diabetes and schizophrenia. Although she was receiving oral anti-diabetes treatment, her HbA1c remained inadequately controlled (8.0–9.0%) partly due her difficulty in following instructions on heathy diet and exercise. In addition, she was repeatedly hospitalized due to suicide attempts by overdosing on her anti-psychotic and anti-diabetes drugs. Her HbA1c was elevated to as high as 10.2% despite the use of multiple anti-diabetes drugs including the GLP-1 receptor agonist dulaglutide, and she was hospitalized in our department. We chose the GLP-1 receptor agonist semaglutide to replace dulaglutide along with a multidisciplinary team approach that included a cognitive–behavioral therapist. The patient perceived that her hunger was suppressed when she started receiving semaglutide 0.5 mg. After discharge, semaglutide was remarkably more effective than dulaglutide in that it reduced and maintained the patient’s HbA1c and body weight for 6 months after initiation of the drug.

Conclusion

The GLP-1 receptor agonist semaglutide can be effective in maintaining appropriate control of glycemia and body weight in diabetes and obesity with schizophrenia.

This is a preview of subscription content, access via your institution.

Fig. 1

Availability of data and materials

Clinical data from the corresponding author are available upon request.

References

  1. Holt RI. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019;19:96.

    Article  Google Scholar 

  2. Kristensen SL, Rorth R, Jhund PS. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    CAS  Article  Google Scholar 

  3. Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatr. 2017;74(7):719–28.

    Article  Google Scholar 

  4. Ishoy PL, Knop FK, Broberg BV, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(2):162–71.

    CAS  Article  Google Scholar 

  5. Yoshimatu H, Sakata T. Behavioral therapy for morbid obesity (in Japanese). Nippon Naika Gakkai Zasshi. 2001;90:902–13.

    Article  Google Scholar 

  6. Suganuma Y, Shimizu T, Sato T, et al. Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2020;11(2):389–99.

    CAS  Article  Google Scholar 

  7. Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275–86.

    CAS  Article  Google Scholar 

  8. Yabe D, Nakamura J, Kaneto H, et al. PIONEER 10 investigators: safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8:392–406.

    CAS  Article  Google Scholar 

  9. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.133429.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Siskind DJ, Russell AW, Gamble C, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050–5.

    CAS  Article  Google Scholar 

  11. Whicher CA, Price HC, Phiri P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021;23(6):1262–71.

    CAS  Article  Google Scholar 

  12. Megna JL, Schwartz TL, Siddiqui UA, et al. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry. 2011;23(2):131–40.

    PubMed  Google Scholar 

  13. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis.” Diabetes Obes Metab. 2001;3(3):195–201.

    CAS  Article  Google Scholar 

  14. Nakamura M, Nakade J, Toyama T, et al. Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report. BMC Pharmacol Toxicol. 2020;21(1):5.

    Article  Google Scholar 

  15. Rotella JA, Wong A. Liraglutide toxicity presenting to the emergency department: a case report and literature review. Emerg Med Australas. 2019;31(5):895–6.

    Article  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the patient for her contribution to this study. The authors also thank J. Kawada, H. Tsuchida and M. Kato for their technical assistance, and M. Yato, Y. Ogiso, and M. Nozu for secretarial assistance.

Funding

This work was supported by grants from Japan Society for the Promotion of Sciences (JSPS) [KAKENHI Grant Number: 26111004 (DY) and 20K19673 (LY)], and Grants for young researchers from Japan Association for Diabetes Education and Care (TK).

Author information

Authors and Affiliations

Authors

Contributions

KN, TK and DY contributed to the analysis, collection, and interpretation of data and writing of the manuscript. NN, MS, SK, TH, YL, YT, KT, MM, TH, TS and YH contributed to the analysis, collection of data, and interpretation of data as well as critical revisions of the manuscript for important intellectual content, and contributed to the analysis, collection and interpretation of pathological data and provided critical revisions of the manuscript for important intellectual content. All authors approved the version to be published. TK and DY are the guarantors of this work.

Corresponding author

Correspondence to Takehiro Kato.

Ethics declarations

Conflict of interest

DY has received consulting/lecture fees from Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Limited. DY also received grants from Arkray Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim, Ono Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, and Terumo Corporation. YH received lecture fees from Kowa and MSD. KN, TK, NN, MS, SK, TH, YL, YT, KT, MM, TH, KI and TS declare that they have no conflict of interest. All authors declare that they have no competing interests relevant to this study.

Ethics approval and consent to participate

Formal ethics approval was waived for this paper by the ethics committee of Gifu University Graduate School of Medicine due to its being a case report.

Compliance with ethical guidelines

All procedures performed in studies involving human participants followed the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Noda, K., Kato, T., Nomura, N. et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetol Int (2022). https://doi.org/10.1007/s13340-022-00590-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13340-022-00590-1

Keywords

  • GLP-1 receptor agonist
  • Schizophrenia
  • Obesity
  • Type 2 diabetes
  • Bodyweight